TRK820 IN PATIENTS WITH HYPONATREMIA COINCIDENT WITH CONGESTIVE HEART FAILURE

TRK-820是一种新型的4，5-环氧吗啉衍生物，设计用于镇痛剂。使用健康志愿者进行的早期临床试验显示了一种意想不到的水生生物效应。从那时起，TRK-820的开发已经扩展到包括考虑该药物在治疗与液体超负荷相关的低钠血症方面的效用。这项研究的主要目标是评估TRK-820在纽约心脏协会III级或IV级心力衰竭合并低钠血症患者中的有效性和安全性。受试者将接受为期5天的静脉注射剂量的TRK-820或安慰剂，每天早上一次。在每个研究日中，将进行血液采样、尿液采集和血流动力学测量。

TRK-820 is a novel 4,5 epoxy-morphinan derivative which was designed and intended for use as an analgesic. Early clinical trials using healthy volunteers demonstrated an unexpected aquaretic effect. Since then, the development of TRK-820 has been extended to include a consideration of the utility of the drug in the treatment of hyponatremia associated with fluid overload. The primary objectives of this research are to evaluate the effectiveness and safety of TRK-820 in patients with hyponatremia coincident with New York Heart Association Class III or IV heart failure. Subjects will be administered an intravenous dose of TRK-820 or placebo once each morning for 5 days. Blood sampling, urine collections, and hemodynamic measurements will be performed throughout each study day.